statistiche ricercatore

BARTALENA, LUIGI

Distribuzione geografica

Continente	#
NA - Nord America	21.739
EU - Europa	13.020
AS - Asia	3.426
Continente sconosciuto - Info sul continente non disponibili	43
SA - Sud America	40
OC - Oceania	21
AF - Africa	14
Totale	38.303

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	21.692
IT - Italia	6.242
UA - Ucraina	2.451
TR - Turchia	1.394
SE - Svezia	953
DE - Germania	902
VN - Vietnam	799
CN - Cina	754
IE - Irlanda	700
FI - Finlandia	597
GB - Regno Unito	491
RU - Federazione Russa	304
SG - Singapore	274
FR - Francia	115
IN - India	67
JP - Giappone	63
EU - Europa	41
NL - Olanda	39
CA - Canada	38
CZ - Repubblica Ceca	36
BE - Belgio	35
ES - Italia	22
BR - Brasile	19
CH - Svizzera	18
AT - Austria	17
CL - Cile	15
LT - Lituania	13
NZ - Nuova Zelanda	13
RO - Romania	13
HK - Hong Kong	12
PK - Pakistan	11
AU - Australia	8
BD - Bangladesh	8
BY - Bielorussia	8
BG - Bulgaria	7
EG - Egitto	6
HU - Ungheria	6
MY - Malesia	6
HR - Croazia	5
IL - Israele	5
LU - Lussemburgo	5
MX - Messico	5
NO - Norvegia	5
AE - Emirati Arabi Uniti	4
EE - Estonia	4
GR - Grecia	4
MD - Moldavia	4
PL - Polonia	4
RS - Serbia	4
SK - Slovacchia (Repubblica Slovacca)	4
AR - Argentina	3
BA - Bosnia-Erzegovina	3
DK - Danimarca	3
ID - Indonesia	3
LK - Sri Lanka	3
PA - Panama	3
SI - Slovenia	3
TZ - Tanzania	3
A2 - ???statistics.table.value.countryCode.A2???	2
AZ - Azerbaigian	2
BN - Brunei Darussalam	2
IQ - Iraq	2
IR - Iran	2
KR - Corea	2
MM - Myanmar	2
PH - Filippine	2
PT - Portogallo	2
TH - Thailandia	2
AM - Armenia	1
BO - Bolivia	1
BT - Bhutan	1
CV - Capo Verde	1
GE - Georgia	1
GL - Groenlandia	1
IM - Isola di Man	1
KE - Kenya	1
KW - Kuwait	1
MA - Marocco	1
NG - Nigeria	1
PE - Perù	1
PY - Paraguay	1
SA - Arabia Saudita	1
TW - Taiwan	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	38.303

Salva come PNG Salva come JPEG

Città	#
Milan	4.534
Fairfield	3.227
Jacksonville	1.896
Woodbridge	1.881
Chandler	1.671
Ashburn	1.567
Houston	1.356
Seattle	1.333
Wilmington	1.246
Cambridge	1.080
Dearborn	1.073
Ann Arbor	971
Izmir	725
Dublin	690
Princeton	678
Nyköping	420
Dong Ket	410
Boardman	400
Rome	328
Singapore	267
Como	239
San Mateo	238
San Diego	201
Chicago	158
New York	133
Ogden	123
Beijing	109
Düsseldorf	86
Hefei	82
Kunming	75
Washington	68
London	66
Zhengzhou	66
Kocaeli	60
Norwalk	60
Dallas	58
Nanjing	57
Tokyo	57
Santa Clara	54
Redmond	51
Los Angeles	41
Helsinki	35
Brussels	34
Jinan	33
Verona	31
Brno	30
Guangzhou	30
Frankfurt am Main	27
Nanchang	25
Munich	24
Shanghai	24
Toronto	24
Pune	19
Kilburn	18
Berlin	15
Edinburgh	15
Hebei	14
Redwood City	13
Shenyang	13
Vienna	13
Madrid	12
Acton	11
Chengdu	11
Fuzhou	11
São Paulo	11
Amsterdam	10
New Bedfont	10
Stockholm	10
Chiswick	9
Detroit	9
Phoenix	9
San Francisco	9
Tappahannock	9
Changsha	8
Piacenza	8
Shaoxing	8
Auburn Hills	7
Auckland	7
Falls Church	7
Hounslow	7
Islamabad	7
Quzhou	7
Sofia	7
Wuhan	7
Zurich	7
Budapest	6
Hanoi	6
Kuala Lumpur	6
Leinì	6
Ningbo	6
Southwark	6
Wandsworth	6
Atlanta	5
Baotou	5
Budrio	5
Chongqing	5
Hyderabad	5
Lappeenranta	5
Mountain View	5
Paris	5
Totale	28.572

Salva come PNG Salva come JPEG

Nome	#
Vitreous Substitutes: The Present and the Future.	253
Macular hole surgery: The healing process of outer retinal layers to visual acuity recovery	233
A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases.	206
Simultaneous medullary and papillary thyroid cancer: two case reports.	200
A 2013 European survey of clinical practice patterns in the management of Graves' disease	188
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	186
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	185
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	185
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012	183
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	181
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	181
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	181
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy	179
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	179
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	170
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	168
The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?	168
Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine	166
Physical performance in newly diagnosed hypothyroidism: a pilot study	166
Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone	165
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO	163
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.	162
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	162
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	161
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy	160
Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy	160
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	159
Studies on the occurrence of ophthalmopathy in Graves' disease	157
Lack of nocturnal serum thyrotropin surge after surgery	155
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	155
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism	155
Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases	154
Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells	154
Interference of thyroglobulin in TSAb detection by radioreceptor assay	154
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	154
Radioactive iodine thyroid uptake in patients with amiodarone iodine-induced thyroid dysfunction	152
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	152
More on smoking habits and Graves' ophthalmopathy	151
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology consensus statement	151
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids	150
The effect of altered thyroid function on serum fructosamine concentrations	149
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	149
Graves' orbitopathy: imperfect treatments for a rare disease	149
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	148
Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism	148
Pain perception, blood pressure levels, and peripheral benzodiazepine receptors in patients followed for differentiated thyroid carcinoma: a longitudinal study in hypothyroidism and during hormone treatment	147
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	146
Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight	146
Shortening Hospital Stay for Thyroid Surgery.	146
Graves' orbitopathy: do not give it for granted	146
Comparison between thyroid-stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease	145
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	145
Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients	144
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	144
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association	144
Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function	143
Cigarette smoking: Number one enemy for Graves ophthalmopathy	143
Effects of the antileukemic drug L-asparaginase on sex-hormone binding globulin: studies in vivo and in vitro	142
Graves'-like orbitopathy: do not forget IgG4-related disease	142
Medullary thyroid carcinoma: surgical treatment advances	142
Graves' disease and Turner's syndrome	141
Diagnosis of amiodarone iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness	141
Changes in radioimmunoassayable prealbumin (TBPA) serum levels from birth to adulthood	141
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	141
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature	141
Treatment of hyperthyroidism in patients with Graves' orbitopathy	141
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	140
Radioiodine therapy and Graves' ophthalmopathy	140
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?	140
The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996	139
Effect of amiodarone on circulating antithyroid antibodies	139
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	139
High prevalence of subacute thyroiditis during summer season in Italy	137
Biosynthesis of a novel thyroxine-binding protein (27 K protein) in human hepatoma (Hep G2) cells	137
Radioimmunoassay of thyroid hormones	136
Polymorphism of human thyroxine-binding globulin	136
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	136
The challenge of orbital decompression in a patient with multiple autoimmune diseases and Graves' orbitopathy: a case report and review of the literature	136
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography	135
Radioreceptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins	135
Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells	135
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement	135
Radioiodine therapy and Graves' ophthalmopathy	134
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	134
Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study	134
Treating Graves' orbitopathy: where are we?	134
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	134
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism	133
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (Hep G2) cells	133
Graves' ophthalmopathy: state of the art and perspectives	133
Orbital radiotherapy for Graves' ophthalmopathy	133
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	133
Ontogeny of nyctohemeral variations of thyrotropin-releasing hormone in rat hypothalamus	132
Management of Graves' ophthalmopathy: reality and perspectives	132
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	132
Amiodarone and the thyroid	132
Long-term safety of orbital radiotherapy for Graves' ophthalmopathy	131
Epidemiology and prevention of Graves' ophthalmopathy	131
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy	131
Radioiodine and thyroid-associated ophthalmopathy	131
Totale	15.180

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	149.470
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	149.470

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	3.885	0	0	0	0	0	0	1.199	977	594	502	132	481
2020/2021	5.749	116	557	194	623	297	643	398	476	823	315	498	809
2021/2022	3.604	378	466	263	137	197	145	175	185	268	573	308	509
2022/2023	4.443	499	248	394	427	322	956	4	544	594	153	179	123
2023/2024	7.528	1.102	1.179	1.142	1.447	1.540	507	55	160	194	55	23	124
2024/2025	1.486	26	70	918	110	107	248	7	0	0	0	0	0
Totale													38.543